Abstract
The monitoring of therapy during the treatment of cancer patients is currently assessed by the levels of circulating tumor cells or by PET/CT scans. Neither approach has the sensitivity or specificity to be very sure of the efficacy of the treatment. Moreover, PET/CT scans can be both comparatively expensive and produce low levels of radiation for the patient. The advent of the possibility of using circulating DNA released from the tumor permits (1) a possible early marker of the presence of the cancer, (2) an indication of the success of the primary treatment, (3) an indication of the early presence of possible metastasis, (4) a marker of the success of secondary subsequent treatment, (5) determining which patients can benefit from a particular treatment, and (6) offering a prognosis. These aspects will be discussed concerning the application of circulating tumor DNA analysis to the monitoring of cancer patients undergoing therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Economopoulos P, Georgoulias V, Kotsakis A (2017) Classifying circulating tumor cells to monitor cancer progression. Expert Rev Mol Diagn 17:153–165
Yan W-T, Cui X, Chen Q et al (2017) Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep 7:43464
Horn P, Jakobsen EH, Madsen JS et al (2016) New approach for interpreting changes in circulating tumour cells (CTC) for evaluation of treatment effect in metastatic breast cancer. Trans Oncol 7:694–701
Tibbe AG, Miller MC, Terstappen LW (2007) Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71:154–162
Allan AL, Keeney M (2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010:426218, 10 p.
Kowalik A, Kowalewska M, Gózdz S (2017) Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. Trans Res 185:58–84
Ashworth TR (1869) A case of cancer in which cells similar to those in tumours were seen in blood after death. Aust Med J 14:146–147
McNamara D (2016) Hidden costs of cancer from CT scans add up. Medscape. Apr 25
Gahan PB (2018) Introduction—liquid biopsies in cancer studies. Trans Cancer Res 7(Suppl 2):S101–S104. https://doi.org/10.21037/tcr.2018.02.10
Gahan PB (2010) Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer. EPMA J 1:503–512
Beck J, Urnovitz HB, Riggert J et al (2009) Profile of the circulating DNA in apparently healthy individuals. Clin Chem 55:730–738
Holdenrieder S, Eichhorn P, Beuers U (2006) Nucleosomal DNA fragments in autoimmune diseases. In: Swaminathan R, Butt A, Gahan PB (eds) Circulating nucleic acids in plasma and serum IV, Ann N Y Acad Sci, vol 1075, Blackwell Publishing, Boston, MA, pp 318–327
Thierry AR, Mouliere F, Gongora C et al (2010) Origin and quantification of circulating DNA in mice and human colorectal cancer xenografts. Nucleic Acid Res 38:6159–6175
Thierry AR, El Messaoudi S, Gahan PB et al (2016) Origins, structures and functions of circulating DNA in oncology. Cancer Metastasis Rev 35:347–376
Stroun M, Anker P, Maurice P et al (1997) Circulating nucleic acids in higher organisms. Int Rev Cytol 51:1–48
Gahan PB, Stroun M (2010) The biology of circulating nucleic acids in plasma and serum. In: Rykova EY, Kikuchi Y (eds) Extracellular nucleic acids, Nucleic acids and molecular biology. Springer, Berlin
Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102(45):16368–16373
Suzuki N, Kamataki A, Yamaki J et al (2008) Characterisation of circulating DNA in healthy human plasma. Clin Chim Acta 387:55–58
Zhong XY, Ladewig A, Schmid S et al (2007) Elevated level of cell free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 276:327–331
Divella R, Tommasi S, Lacalamita R et al (2009) Circulating hTERT DNA in early breast cancer. Anticancer Res 29:2845–2849
Schwarzenbach H, Stoehlmacher J, Pantel K et al (2008) Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci 1137:190196
Mouliere F, El Messaoudi S, Gongora C et al (2013) Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol 6:319–328
Thierry AR, Mouliere F, Gongora C et al (2010) Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38:6159–6175
El Messaoudi S, Mouliere F, Du Manoir S et al (2016) Circulating DNA as a strong multi-marker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res 22:3067–3077
Nygaard AD, Holdgaard PC, Spindler KL et al (2014) The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer 110:363–368
El Messaoudi S, Thierry A (2015) Pre-analytical requirements for analysing nucleic acids from blood. In: Gahan PB (ed) Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, Advances in predictive, preventive medicine, vol 5. Springer, Dordrecht, pp 45–70
Holdenrieder S (2015) CNAPS in therapy monitoring. In: Gahan PB (ed) Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, Advances in predictive, preventive medicine, vol 5. Springer, Dordrecht, pp 325–370
Tamkovich SN, Bryzgunova OE, Rykova EY (2005) Circulating nucleic acids in blood of healthy male and female donors. Clin Chem 51:1317–1319
Ledoux L, Charles P (1972) Fate of exogenous DNA in mammals. In: Ledoux L (ed) Uptake of informative molecules by living cells. North-Holland Publishing Co., Amsterdam, pp 397–413
Gosse C, Le Pecq JB, Defrance P et al (1965) Initial degradation of deoxyribonucleic acid after injection in mammals. Cancer Res 25:877–883
Tsumita T, Iwagana M (1963) Fate of injected deoxyribonucleic acid in mice. Nature 198:1088–1089
Gauthier VJ, Tyler LN, Mannik M (1996) Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol 156:1151–1156
Lo YMD, Zhang J, Leung TN et al (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218–224
Adams DH, Gahan PB (1982) Stimulated and non-stimulated rat spleen cells release different DNA-complexes. Differentiation 22:47–52
Adams DH, Gahan PB (1983) The DNA extruded by rat spleen cells in culture. Int J Biochem 15:547–552
Adams DH, Diaz N, Gahan PB (1997) In vitro stimulation by tumour cell media of [3H]thymidine incorporation by mouse spleen lymphocytes. Cell Biochem Funct 15:119–126
Gahan PB, Stroun M (2010) Biology of CNAPS. In: Yo Kikuchi Y, Rykova EY (eds) Extracellular nucleic acids, Nucleic acids and molecular biology. Springer, Berlin, pp 167–189
Zhang R, Nakahira K, Guo X et al (2016) Very short mitochondrial DNA fragments and heteroplasmy in human plasma. Sci Rep 6:36097
Strydom C, Robinson C, Pretorius E et al (2006) The effect of selected metals on the central metabolic pathways in biology. Water SA 32:543–554
Mouliere F, Robert B, Peyrotte EA et al (2011) High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6:e23418
Holdenrieder S, Stieber P, Bodenmueller H et al (2001) Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 95:114–120
Holdenrieder S, Stieber P, von Pawel J et al (2004) Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10:5981–5987
Holdenrieder S, Stieber P, von Pawel J et al (2006) Early and specific prediction of the therapeutic efficiency in lung cancer by nucleosomal DNA and cytokeratin fragments. Ann N Y Acad Sci 1075:244–257
Kremer A, Holdenrieder S, Stieber P et al (2006) Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol 27:235–242
Wittwer C, Boeck S, Heinemann V et al (2013) Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 133:2619–2630
Stoetzer OJ, Ferching DM, Salat C et al (2013) Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating nucleosomes. Cancer Lett 336:140–148
Nagata S, Nagase H, Kawane K et al (2003) Apoptosis at a glance: death or life? Cell Death Differ 10:108–116
Nagata S (2005) DNA degradation in development and programmed cell death. Ann Rev Immunol 23:853–875
Grunt M, Hillebrand T, Schwarzenbach H (2018) Clinical relevance of size selection of circulating DNA. Transl Cancer Res 7:S171
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437
Jiang P, Chan CW, Chan KC et al (2015) Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 112:E1317–E1325
Zheng YW, Chan KC, Sun H et al (2012) Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. Clin Chem 58:549–558
Schwarzenbach H, Pantel K (2015) Circulating DNA as biomarker in breast cancer. Breast Cancer Res 17:136
Chandrananda D, Thorne NP, Bahlo M (2015) High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med Genet 8:29
Lo YM, Chan KC, Sun H et al (2010) Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2:61ra91
Wang M, Block TM, Steel L et al (2004) Preferential isolation of fragmented DNA enhances the detection of circulating k-ras DNA. Clin Chem 50:211–213
Moser T, Ulz P, Zhou Q et al (2017) Single-stranded DNA library preparation does not preferentially enrich circulating tumor DNA. Clin Chem 63:1656–1659
Heidary M, Auer M, Ulz P et al (2014) The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 16:421
Heitzer E, Auer M, Hoffmann EM et al (2013) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 133:346–356
Oellerich M, Schütz E, Beck J et al (2017) Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci 54:205
Schmidt B, Fleischhacker M (2018) Is liquid biopsy ready for the litmus test and what has been achieved so far to deal with pre-analytical issues? Transl Cancer Res 7:S130
Ladas I, Fitarelli-Kiehl M, Song C (2017) Multiplexed elimination of wild-type DNA and high-resolution melting prior to targeted resequencing of liquid biopsies. Clin Chem 63:1605–1613
Gahan PB (2015) A brief history and the present and future status of CNAPS. In: Gahan PB (ed) Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, Advances in predictive, preventive medicine, vol 5. Springer, Dordrecht, pp 3–14
Pan W, Quake SR (2015) Genomic approaches to the analysis of cell free nucleic acids. In: Gahan PB (ed) Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, Advances in predictive, preventive medicine, vol 5. Springer, Dordrecht, pp 113–139
Zhou Q, Moser T, Perakis S et al (2018) Untargeted profiling of cell-free circulating DNA. Transl Cancer Res 7:S140–S152. https://doi.org/10.21037/tcr.2017.10.11
Roschewski M, Staudt LM, Wilson WH (2016) Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood 127:3127–3132
Berger AW, Schwerdel D, Welz H et al (2017) Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS One 12(3):e0174308. https://doi.org/10.1371/journal.pone.0174308
Swisher EM, Wollan M, Mahtani SM et al (2005) Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 193:662–667
Thålin C, Lundström S, Seignez C et al (2018) Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer. PLoS One 13:e0191231
Cohen JD, Javed AA, Thoburn C et al (2017) Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A 114:10202–10207
Cohen JD, Li L, Wang Y et al (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926–930
Snyder MW, Kircher M, Hill AJ et al (2016) Cell-free DNA compromises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:57–68
Seufferlein T, Schwerdel D, Welz H et al (2017) Treatment monitoring of metastatic colorectal cancer by quantification and genotyping of mutated KRAS in circulating cell-free DNA. J Clin Oncol 35:e15037. https://doi.org/10.1200/JCO.2017.35.15_suppl.e15037
Chen T, He R, Hu X et al (2017) Circulating tumour DNA: a potential biomarker from solid tumors’ monitor to anticancer therapies. Cancer Transl Med 3:64–67
Shu Y, Wu X, Tong X et al (2017) Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep 7:583
Forshew T, Murtaza M, Parkinson C et al (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4:136ra68. https://doi.org/10.1126/scitranslmed.3003726
Abbosh C, Birkbak NJ, Wilson GA et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446–451
Perets P, Greenberg O, Shenter T et al (2018) Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. Oncologist 23:566–572. https://doi.org/10.1634/theoncologist.2017-0467
Schiavon G, Hrebien S, Garcia-Murillas I et al (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7:313ra182. https://doi.org/10.1126/scitranslmed.aac7551
Mohan S, Heitzer E, Ulz P et al (2014) Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 10:e1004271. https://doi.org/10.1371/journal.pgen.1004271
Thierry AR, El Messaoudi S, Mollevi C et al (2017) Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol 28:2149–2159
Diaz LA, Williams R, Wu J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540
Diaz LA, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586
Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
Misale S, Yaeger R, Hobor S et al (2012) Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer. Nature 486:532–536
Murtaza M, Dawson S-J, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112
Bettegowda C, Sausen M, Leary RL et al (2014) Detection of circulating tumor DNA in early- and late-stage malignancies. Sci Trans Med 6:224ra24. https://doi.org/10.1126/scitranslmed.3007094
Singh AP, Li S, Cheng H (2017) Circulating DNA in EGFR-mutated lung cancer. Ann Transl Med 5:379. https://doi.org/10.21037/atm.2017.07.10
Dawson S-J, Tsui DWY, Murtaza M et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209
Sirera R, Bremnes RM, Cabrera A et al (2011) Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:286–290
Tissot C, Toffart A-C, Villar S et al (2015) Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J 46:1773–1780
Sunami E, Shinozaki M, Higano CS et al (2009) Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 55:559–567
Singh N, Gupta S, Pandey RM et al (2015) High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival. Cancer Investig 33:78–85
Gootenberg JS, Abudayyeh OO, Kellner MJ et al (2018) Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. Science 360:439–444. https://doi.org/10.1126/science.aaq0179
Gröbner SN, Worst BC, Weischenfeldt J et al (2018) The landscape of genomic alterations across childhood cancers. Nature 555:321–327
Ma X, Yu L, Yanling L et al (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371–376
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Gahan, P.B. (2019). Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential. In: Casadio, V., Salvi, S. (eds) Cell-free DNA as Diagnostic Markers. Methods in Molecular Biology, vol 1909. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8973-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8973-7_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8972-0
Online ISBN: 978-1-4939-8973-7
eBook Packages: Springer Protocols